Insulet generated fourth quarter revenue of 783800000, up 31.2% year-over-year, led by 33.5% growth in Total Omnipod revenue. Gross margin expanded to 72.5% and operating income reached 146300000, representing 18.7% of revenue. Net income was 101600000 with diluted EPS of 1.44.

Insulet delivered robust third-quarter results, with revenue reaching $706.3 million, a 29.9% increase year-over-year, driven by strong Omnipod product growth. The company exceeded its revenue guidance and raised its full-year revenue and margin guidance, reflecting the strong performance of its Omnipod 5 system.

Insulet delivered robust second quarter 2025 results, with total revenue increasing by 32.9% year-over-year to $649.1 million, driven by strong performance in both U.S. and International Omnipod segments. The company also saw significant improvements in gross margin, operating income, and adjusted EBITDA, while raising its full-year revenue and adjusted operating margin guidance.

Insulet delivered a strong first quarter in 2025, exceeding expectations with significant revenue growth driven by the Omnipod platform. The company also saw improvements in profitability metrics and raised its full-year guidance.

Insulet Corporation achieved solid financial results in Q4 2024, reporting revenue of $597.5 million, up 17.2% YoY. The company's Omnipod revenue saw strong growth both in the U.S. and internationally. Adjusted EPS was $1.15, and free cash flow improved significantly. Gross margin increased to 72.1%.

Insulet reported strong third-quarter results, with revenue reaching $543.9 million, a 25.7% increase year-over-year. The company raised its full-year revenue and margin guidance, driven by the success of Omnipod 5 and its recent FDA clearance for type 2 diabetes.

Insulet Corporation reported a 23% year-over-year increase in revenue for the second quarter of 2024, reaching $488.5 million. The company raised its full-year revenue, gross margin, and operating margin guidance due to strong Omnipod 5 demand and product innovation.

Insulet Corporation reported a 23% year-over-year increase in revenue for the first quarter of 2024, exceeding guidance. The company raised its full-year revenue and operating margin outlook due to strong performance across all product lines and strategic launches.

Insulet Corporation reported Q4 2023 revenue of $509.8 million, a 37.9% increase year-over-year. The company's growth was fueled by the rapid adoption of Omnipod 5 and strong execution. They are well-positioned for continued profitable growth and value creation.

Insulet Corporation reported a strong third quarter with a 27% increase in revenue compared to the previous year, driven by high demand for Omnipod 5. The company raised its full-year revenue guidance to a range of 26% to 27%.

Insulet Corporation reported a strong second quarter with a 32.4% increase in revenue, driven by Omnipod demand. The company commercially launched Omnipod 5 in the UK and submitted the Omnipod 5 iOS App to the FDA.

Insulet Corporation reported a 21.2% year-over-year increase in revenue for the first quarter of 2023, reaching $358.1 million. The growth was primarily driven by a significant increase in U.S. Omnipod revenue. The company is on track with the international roll-out of Omnipod 5.

Insulet Corporation reported a strong fourth quarter in 2022, with revenue reaching $369.7 million, a 20.1% increase compared to the previous year. The growth was primarily fueled by a 32.8% increase in total Omnipod revenue, with significant contributions from the U.S. market. The company's strategic priorities and the commercial launch of Omnipod 5 contributed to the positive results.

Insulet Corporation announced financial results for Q3 2022, with revenue reaching $340.8 million, a 23.7% increase compared to the previous year. The company experienced growth in U.S. Omnipod revenue, while international Omnipod revenue decreased slightly. Insulet launched the U.S. full market release of the Omnipod® 5 Automated Insulin Delivery System and secured CE Marking for Omnipod 5 under the European Medical Device Regulation.

Insulet reported strong second-quarter results with revenue exceeding guidance, driven by growth in Omnipod, particularly in the U.S., and highlighted strategic advancements including the full market release of Omnipod® 5 in the U.S.

Insulet Corporation reported a 17.1% increase in revenue for the first quarter of 2022, reaching $295.4 million. The growth was driven by strong global Omnipod adoption and the ongoing commercial launch of the Omnipod 5 Automated Insulin Delivery System. The company's financial results exceeded guidance, with a gross margin of 71.0% and operating income of $37.9 million.

Insulet Corporation reported a strong fourth quarter in 2021, with revenue reaching $307.7 million, a 25% increase compared to the previous year. The company's success was driven by significant growth in U.S. Omnipod and Drug Delivery revenue, contributing to an operating income of $49.7 million and a net income of $29.2 million.

Insulet Corporation reported a strong third quarter with revenue reaching $275.6 million, an increase of 17.8% compared to the prior year. The company saw growth across its Omnipod product line, particularly in the U.S., and achieved record new customer starts. Insulet is on track for Omnipod 5 clearance later this year.

Insulet Corporation reported second quarter 2021 revenue of $263.2 million, up 16.3% compared to the prior year. Total Omnipod revenue increased by 19.9%, driven by growth in both U.S. and International markets. The company is reaffirming its revenue guidance range of 16% to 20% for the year ending December 31, 2021.

Insulet reported strong first quarter results with revenue reaching $252.3 million, a 27.4% increase compared to the prior year. The company achieved the high end of its guidance, driven by growth in Omnipod and Drug Delivery revenues. Insulet is excited for the commercial launch of Omnipod 5.

Insulet Corporation reported a strong finish to 2020 with an 18% increase in revenue for the fourth quarter, reaching a record quarterly revenue of $246.1 million. The company also celebrated a milestone of 250,000 global customers using the Omnipod System.

Insulet Corporation reported strong financial results for the third quarter of 2020, with revenue reaching $234.0 million, a 21.8% increase compared to the previous year. The company's performance exceeded expectations, driven by innovation and a recurring revenue model. Insulet raised its full-year revenue outlook and anticipates delivering its fifth consecutive year of 20% growth.

Insulet Corporation announced financial results for the three months ended June 30, 2020, with second quarter revenue of $226.3 million, up 27.8% compared to the prior year. The company's strong financial profile allows them to continue to invest in their business and advance important initiatives.

Insulet Corporation reported a strong first quarter in 2020, with revenue reaching $198.0 million, a 24.1% increase year-over-year. Total Omnipod revenue grew by 32.7% to $189.7 million. The company's gross margin was 64.1%, and adjusted EBITDA was $24.3 million, representing 12.3% of revenue. However, the company experienced a net loss of $2.1 million, or $(0.03) per diluted share.

Insulet Corporation reported a strong Q4 2019 with revenue reaching $209.4 million, a 27% increase year-over-year, exceeding the company's guidance. The company's Omnipod products saw significant growth, particularly in the US. Insulet is progressing towards its 2021 financial goals.